PP_1170x120_10-25-21

Xultophy 100/3.6

Novo Nordisk releases Xultophy 100/3.6 insulin pen

Novo Nordisk releases Xultophy 100/3.6 insulin pen

PLAINSBORO, N.J. — Novo Nordisk has launched Xultophy 100/3.6, a combination therapy insulin pen, at pharmacies nationwide. Xultophy 100/3.6 combines the long-acting basal insulin Tresiba (insulin degludec U-100) with the No. 1-prescribed glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy Victoza (liraglutide 3.6 mg/ml) in a once-daily injection, Novo Nordisk said. The prefilled pen is indicated as

Adheris Health